Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Medical Officer

President and CEO

Chief Scientific Officer

Chief Operations Officer

Chief Financial Officer

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodul...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2023-09-25	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2023-09-25	Premium	sold	Premium	Premium	Premium	President and CEO
2023-05-31	Premium	gifted	Premium	Premium	Premium	Chief Scientific Officer
2023-05-30	Premium	gifted	Premium	Premium	Premium	Chief Scientific Officer
2023-01-05	Premium	sold	Premium	Premium	Premium	Chief Scientific Officer
2023-01-05	Premium	sold	Premium	Premium	Premium	President and CEO
2023-01-05	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2023-01-05	Premium	sold	Premium	Premium	Premium	Chief Operations Officer
2023-01-04	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2023-01-04	Premium	sold	Premium	Premium	Premium	Chief Operations Officer
2023-01-04	Premium	sold	Premium	Premium	Premium	President and CEO
2023-01-04	Premium	sold	Premium	Premium	Premium	Chief Scientific Officer
2023-01-02	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2023-01-02	Premium	acquired	Premium	Premium	Premium	President and CEO
2023-01-02	Premium	acquired	Premium	Premium	Premium	Chief Scientific Officer
2023-01-02	Premium	acquired	Premium	Premium	Premium	Chief Operations Officer
2022-12-05	Premium	sold	Premium	Premium	Premium	President and CEO
2022-12-01	Premium	acquired	Premium	Premium	Premium	President and CEO
2022-09-02	Premium	sold	Premium	Premium	Premium	President and CEO
2022-09-01	Premium	acquired	Premium	Premium	Premium	President and CEO
2022-06-13	Premium	bought	Premium	Premium	Premium	-
2022-06-01	Premium	acquired	Premium	Premium	Premium	President and CEO
2022-05-09	Premium	bought	Premium	Premium	Premium	-
2022-04-11	Premium	bought	Premium	Premium	Premium	-
2022-03-02	Premium	sold	Premium	Premium	Premium	President and CEO

SELB - Selecta Biosciences Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for SELB